Ivabradin Puren

Ivabradine, the active ingredient in Ivabradin Puren, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is indicated for chronic stable angina and for heart failure in patients with reduced ejection fraction, improving symptoms and functional capacity.

GNH USA supplies Ivabradin Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch, including certificates of analysis and import permits.

Ivabradine acts on the cardiac sinus node to reduce heart rate, and is used in specific cardiovascular conditions.

- Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. - Heart failure (NYHA class II–III) with reduced ejection fraction: lowers heart rate, decreasing myocardial oxygen demand and may improve symptoms and functional capacity.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Phosphenes (luminous phenomena) - Headache - Dizziness - Fatigue

Serious or Rare Side Effects: - Symptomatic bradycardia - Atrial fibrillation - Severe visual disturbances

Before initiating therapy, consider the following precautions.

- Heart‑rate monitoring: ensure resting heart rate is ≥60 bpm before starting. - Hepatic impairment: use with caution in moderate to severe liver disease. - Sick sinus syndrome: avoid in patients with known sinus node dysfunction. - Concomitant beta‑blockers: monitor for excessive bradycardia when combined. - Acute decompensated heart failure: contraindicated during unstable phases. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Ivabradine may interact with several medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) – may increase plasma levels. - Calcium‑channel blockers that depress conduction (verapamil, diltiazem) – risk of pronounced bradycardia. - Other If‑channel inhibitors – additive heart‑rate reduction.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin) – may reduce efficacy. - Digoxin – monitor for combined effects on heart rate. - Antihypertensive agents – watch for additive blood pressure lowering.